Every material Form 8-K Viatris filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Viatris reported third-quarter 2025 total revenues of $3.8 billion, flat on a reported basis, and a U.S. GAAP net loss of $128 million, compared with net earnings of $95 million a year earlier. The company attributed the loss mainly to a reduction in the fair value of its Biocon Biologics preferred shares and higher income tax expense, and it raised and narrowed its 2025 guidance ranges for total revenues, adjusted EBITDA and adjusted EPS.
Q3 2025 total revenues were $3.8 billion, flat reported and down 1% on a divestiture-adjusted operational basis; the estimated Indore Impact was about $100 million in the quarter.
Q3 2025 U.S. GAAP net loss was $(128) million, or $(0.11) per share, versus net earnings of $95 million, or $0.08 per share, in Q3 2024; adjusted EPS was $0.67, down 11% reported.
2025 guidance now shows total revenues of $13.9 billion to $14.3 billion (previously $13.5 billion to $14.0 billion) and adjusted EPS of $2.25 to $2.35 (previously $2.16 to $2.30).
Year-to-date, Viatris returned more than $920 million to shareholders, including $500 million in share repurchases.
Viatris reported second quarter 2025 results with total revenues of $3.6 billion, down 6% from a year earlier, and adjusted EPS of $0.62, down 10%. The company reaffirmed its 2025 guidance ranges and said it expects to land in the top half of the range for total revenues and adjusted EPS, which matters to shareholders because the company attributes the declines mainly to the Indore Impact.
Q2 2025 total revenues were $3.6 billion, down 6% reported and down 2% on a divestiture-adjusted operational basis versus Q2 2024.
U.S. GAAP net loss narrowed to $(5) million from $(326) million a year earlier; adjusted EPS was $0.62 versus $0.69.
The estimated Indore Impact reduced Q2 2025 total revenues by approximately $160 million.
2025 guidance reaffirmed: total revenues $13,500 million to $14,000 million and adjusted EPS $2.16 to $2.30; year-to-date capital returned exceeded $630 million, including $350 million in share repurchases.
Viatris expanded its Board from 14 to 15 members and appointed David Simmons as an independent director, effective immediately, with a term expiring at the 2025 annual meeting. The company has not yet named committee assignments, which it says it will disclose in a later amendment to this filing.
Board increased from 14 to 15 members; David Simmons appointed on August 4, 2025, with a term ending at the 2025 annual meeting
Simmons is the CEO of Caliber Holdings Corporation and previously served as Chairman and CEO of PPD, Inc.
He spent more than 15 years at Pfizer Inc., including overseeing its Established Products Unit
Simmons will receive compensation consistent with other non-employee directors, and the company has an indemnification agreement with him
Viatris reported first quarter 2025 total revenues of $3.3 billion, down 11% from a year earlier, and a U.S. GAAP net loss of $3.0 billion, driven by a non-cash goodwill impairment charge of $2.9 billion. Adjusted EPS was $0.50, down 25%, and the company reaffirmed its 2025 outlook, including adjusted EPS guidance of $2.16 to $2.30. The filing also says the company has returned more than $450 million to shareholders year to date.
Total revenues $3.3 billion (down 11% reported; down 2% divestiture-adjusted operational basis); Indore Impact estimated at approximately $140 million in the quarter
U.S. GAAP net loss $(3.0) billion, or $(2.55) per share, versus net earnings of $114 million, or $0.09 per share, a year earlier
Adjusted EPS $0.50 versus $0.67 a year earlier; adjusted EBITDA $923.5 million, down 23%
2025 guidance reaffirmed; share repurchases of $500 million to $650 million expected in 2025
Viatris appointed Frank D'Amelio, former Pfizer CFO, and Michael Severino, M.D., former AbbVie executive, to its Board of Directors effective May 5, 2025, expanding the Board from 12 to 14 seats. Directors Rajiv Malik and Harry Korman will retire at the end of their current terms in December 2025, following the 2025 Annual Meeting. The filing reports no financial results, and it describes a Board change rather than a financial event.
Board size increased from 12 to 14 directors, effective May 5, 2025
Frank D'Amelio joins the Finance Committee; Michael Severino joins the Science and Technology Committee
Rajiv Malik and Harry Korman will not stand for re-election at the 2025 Annual Meeting and will retire at the end of their current terms
Retirements were not the result of any disagreement with the company on operations, policies, or practices
On February 27, 2025, Viatris reported fourth quarter and full-year 2024 results and issued 2025 guidance. Full-year 2024 total revenues were $14.7 billion, down 5% as reported, and the U.S. GAAP net loss was $634.2 million, compared with net earnings of $54.7 million in 2023. The company guided 2025 total revenues to $13.5 billion to $14.0 billion and adjusted EPS to $2.12 to $2.26, and said an FDA import alert at its Indore facility is expected to reduce 2025 total revenues by about $500 million and adjusted EBITDA by about $385 million.
Full-year 2024 total revenues were $14.7 billion, down 5% as reported; adjusted EPS was $2.65, versus $2.93 in 2023.
U.S. GAAP net loss was $(634.2) million for 2024, compared with net earnings of $54.7 million in 2023.
2025 guidance: total revenues of $13.5 billion to $14.0 billion and adjusted EPS of $2.12 to $2.26.
Indore facility impact is estimated at about $500 million to 2025 total revenues and about $385 million to adjusted EBITDA; the company plans $500 million to $650 million in 2025 share repurchases.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Viatris filing is on SEC EDGAR ↗. 8-K briefs of other companies →